Gemfibrozil
- Generic Name
- Gemfibrozil
- Brand Names
- Lopid
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22O3
- CAS Number
- 25812-30-0
- Unique Ingredient Identifier
- Q8X02027X3
- Background
Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.
Gemfibrozil was granted FDA approval on 21 December 1981.
- Indication
Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions. Gemfibrozil is also indicated to reduce the risk of developing coronary h...
- Associated Conditions
- Coronary Heart Disease (CHD), Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia
- Associated Therapies
- -
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06392659
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT06064539
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT05932303
- Locations
- 🇨🇦
Local Institution - 0001, Québec, CA, Canada
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Forest Hills Lab
- Target Recruit Count
- 32
- Registration Number
- NCT05931484
A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05069870
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04956627
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03723395
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT03624959
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Actelion
- Target Recruit Count
- 40
- Registration Number
- NCT02770222
- Locations
- 🇩🇪
Investigator Site, Kiel, Germany
Gemfibrozil for Nicotine Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02638597
- Locations
- 🇺🇸
Parkland Memorial Hospital, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.